Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021294
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:07
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11202
  Complete submission text file 0000950170-25-021294.txt   13063
Mailing Address 4F, BUILDING C14, NO. 218, XINGHU STREET SUZHOU INDUSTRIAL PARK JIANGSU F4 00000
Business Address 4F, BUILDING C14, NO. 218, XINGHU STREET SUZHOU INDUSTRIAL PARK JIANGSU F4 00000 86-512-87773632
Adagene Inc. (Subject) CIK: 0001818838 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92270 | Film No.: 25629607
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 86 21 60252100
Panacea Innovation Ltd (Filed by) CIK: 0002010692 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A